The US Food and Drug Administration (FDA) has granted approval to ViiV Healthcare, a specialist HIV healthcare company, for its two-drug regimen (2DR), Juluca, intended to treat certain adults with human immunodeficiency virus type 1, it was reported yesterday.
The product is said to be the first 2DR, which includes dolutegravir 50mg produced by ViiV Healthcare and rilpivirine 25mg produced by Janssen Therapeutics. It has been approved as a complete regimen for the maintenance treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen for around six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of the product.
The approval was based on data from two pivotal phase III clinical trials, known as Sword-1 and Sword-2.
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD